Crinetics Pharmaceuticals, Inc. (CRNX)

45,33 -1,56 (-3,33 %) À la clôture : 04:00PM EDT

Crinetics Pharmaceuticals, Inc.

6055 Lusk Boulevard
San Diego, CA 92121
United States
858 450 6464
https://www.crinetics.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 290

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. R. Scott Struthers Ph.D.	Founder, President, CEO & Director	978,34k	5,65M	1963
Dr. Stephen F. Betz Ph.D.	Founder & Chief Scientific Officer	672,66k	S.O.	1966
Mr. Marc J. C. Wilson	Chief Financial Officer	642,25k	408,5k	1979
Mr. Jeff E. Knight	Chief Operating Officer	657,31k	S.O.	1971
Dr. Alan S. Krasner M.D.	Chief Endocrinologist	653,92k	125,93k	1963
Mr. James Hassard	Chief Commercial Officer	623,5k	S.O.	1966
Ms. Garlan Adams	General Counsel & Corporate Secretary	S.O.	S.O.	S.O.
Ms. Adriana Cabre M.B.A.	Chief Human Resources Officer	S.O.	S.O.	S.O.
Mr. Kevin Capps	Head of Intellectual Property	S.O.	S.O.	S.O.
Mr. Chris Robillard M.B.A.	Chief Business Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Crinetics Pharmaceuticals, Inc. en date du 1 juin 2024 est 7. Les scores principaux sont Audit : 2; Société : 6; Droits des actionnaires : 8; Compensation : 9.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.